Amy V. Kapp
Impact in
- Oncology top 2%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- HER2/EGFR in Cancer Research
- Immunology top 5%
- Immunotherapy and Immune Responses
Papers in
- Oncology 21
- HER2/EGFR in Cancer Research 7
- Cancer Treatment and Pharmacology 5
- Lung Cancer Research Studies 3
- Co-authors
- Robert Tibshirani (4 shared papers)Mark R. Middleton (1 shared paper)Steinar Aamdal (1 shared paper)Neil K. Aaronson (1 shared paper)Gerhard Fierlbeck (1 shared paper)Uwe Fraass (1 shared paper)Martin Gore (1 shared paper)Wolfgang Tilgen (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)Cancer Research (5 papers)Annals of Oncology (2 papers)BMC Genomics (2 papers)Blood (1 paper)
- Partner nations
- United StatesSpainSouth Korea
In The Last Decade
Amy V. Kapp
30 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 1.2k
- Immunology 438
- Genetics 146
- Molecular Biology 909
- Cancer Research 195
Countries citing papers authored by Amy V. Kapp
This map shows the geographic impact of Amy V. Kapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy V. Kapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy V. Kapp more than expected).
Fields of papers citing papers by Amy V. Kapp
This network shows the impact of papers produced by Amy V. Kapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy V. Kapp. The network helps show where Amy V. Kapp may publish in the future.
Co-authors
The 25 scholars most cited alongside Amy V. Kapp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Hit paper breakdown → | 2000 | 936 |
| 2 | 2020 | 191 | |
| 3 | 2006 | 127 | |
| 4 | 2006 | 90 | |
| 5 | 2016 | 84 | |
| 6 | 2007 | 67 | |
| 7 | 2013 | 50 | |
| 8 | 2015 | 49 | |
| 9 | 2015 | 36 | |
| 10 | 2016 | 36 | |
| 11 | 2017 | 25 | |
| 12 | 2018 | 20 | |
| 13 | 2014 | 15 | |
| 14 | 2012 | 13 | |
| 15 | 2011 | 10 | |
| 16 | 2012 | 7 | |
| 17 | 2007 | 5 | |
| 18 | 2024 | 5 | |
| 19 | 2011 | 5 | |
| 20 | 2015 | 5 |
About Amy V. Kapp
Amy V. Kapp is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Cancer Research, having authored 30 papers that have together received 1.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Cancer Genomics and Diagnostics (4 papers), Lung Cancer Research Studies (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Oncology (1.2k citations), Immunology (438 citations), Genetics (146 citations), Molecular Biology (909 citations) and Cancer Research (195 citations). Amy V. Kapp has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include Robert Tibshirani, Mark R. Middleton, Steinar Aamdal, Neil K. Aaronson, Gerhard Fierlbeck, Uwe Fraass, Martin Gore, Wolfgang Tilgen, Brigitte Dréno and Simone Seiter. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, BMC Genomics and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.